Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6793 and Metformin in Type 2 Diabetes Mellitus
NCT07433062Phase 1Suspended
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD6793 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Mean glucose levels at Day 7. Started Jan 2026; status: suspended.
02
Drugs
AZD6793
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07433062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07433062.